Bruker (BRKR) shares are in focus after the company announced the European launch of its fully automated MyGenius PRO molecular diagnostics system, along with a broad set of upgrades to its MALDI Biotyper infectious disease tools.

Despite the product launches around MyGenius PRO and the upgraded MALDI Biotyper tools, momentum in the share price has been soft. The 7 day share price return is 9.55% and the year to date share price return is 24.63%, while the 3 year total shareholder return of 53.12% highlights how challenging the longer stretch has been.

If this infection diagnostics story has your attention, it can be useful to see what else is moving in related areas through 32 healthcare AI stocks.

With Bruker’s infection diagnostics portfolio expanding, yet the share price showing a 24.63% year-to-date decline and a 53.12% three-year total return decline, should you see value here or assume markets are already pricing in future growth?

Most Popular Narrative: 24.2% Undervalued

Bruker’s most followed valuation narrative places fair value at $47.86 per share, compared with the last close of $36.26, which sets up a sizable gap for investors to assess.

The company's pipeline of recent innovations (e.g., next-generation tims mass spectrometry, spatial biology, automated diagnostics) positions it to benefit from sustained investment in personalized medicine, genomics, and high-throughput scientific R&D, supporting both future revenue expansion and favorable product mix improvements.

Read the complete narrative. Read the complete narrative.

Want to understand why the fair value sits well above today’s share price? The narrative focuses on factors such as faster earnings growth, rising margins, and a richer product mix. Curious how those moving parts translate into the long term valuation gap?

Result: Fair Value of $47.86 (UNDERVALUED)

However, this hinges on research funding stabilising and helium costs staying manageable, as deeper funding cuts or sustained input pressures could quickly erode those assumptions.

Another View: DCF Suggests Bruker Is Slightly Overvalued

The popular narrative points to a fair value of $47.86 per share, yet Simply Wall St’s DCF model estimates Bruker’s future cash flow value at $35.82, just below the current $36.26 price. If cash flows are the anchor, is the upside story already reflected?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Bruker for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Seeing both enthusiasm and concern in the numbers and narratives so far, it makes sense to move quickly and weigh the trade off yourself using the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Bruker has you thinking more broadly about your portfolio, this is a good moment to scan for other opportunities that fit your style before the next move passes you by.

• Target potential upside across quality names by checking out the 53 high quality undervalued stocks that might sit below what you think they are worth.
• Strengthen your income stream by reviewing the 14 dividend fortresses that focus on higher yields with an emphasis on resilience.
• Prioritise resilience and capital preservation by screening through 72 resilient stocks with low risk scores that may suit a more cautious approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.